XML 48 R38.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Commitments and Contingencies - Additional Information (Detail) |  | 6 Months Ended |
--- | --- | --- | ---
May 24, 2018 USD ($) | Jun. 30, 2018 USD ($) | Jun. 30, 2018 GBP (£)
Further Indication for AMR101 | Marketing Approval In Europe |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |
Potential aggregate stock or cash payment |  | $ 9,900,000 | £ 7,500,000
Further Indication for AMR101 | Potential Marketing Approval 1 |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |
Potential aggregate stock or cash payment |  | 6,600,000 | 5,000,000
Further Indication for AMR101 | Potential Marketing Approval 2 |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |
Potential aggregate stock or cash payment |  | 6,600,000 | 5,000,000
Further Indication for AMR101 | Maximum |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |
Potential aggregate stock or cash payment |  | 13,200,000 | £ 10,000,000
Nisshin |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |
Royalty, milestone or minimum purchase commitments |  | $ 0 |
Teva |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |
Payment made to Teva | $ 2,000,000 |  |

X
- Definition Commitments and contingencies disclosure. + References No definition available. + Details
Name: | amrn_CommitmentsAndContingenciesDisclosureLineItems
Namespace Prefix: | amrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty, milestone or minimum purchase commitments. + References No definition available. + Details
Name: | amrn_RoyaltyMilestoneOrMinimumPurchaseCommitments
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount the entity has committed to make for future royalty guarantees. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 928 -SubTopic 440 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013 + Details
Name: | us-gaap_RoyaltyGuaranteesCommitmentsAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_StatementScenarioAxis=amrn_FurtherIndicationForAMROneZeroOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_MarketingApprovalInEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_PotentialMarketingApprovalOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_PotentialMarketingApprovalTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amrn_NisshinPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=amrn_TevaPharmaceuticalsUSAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |